Hereditary Hemorrhagic Telangiectasia (HHT) Center
This grant supports clinical partnerships, better diagnosis, and a patient data registry to improve care and outcomes for people with Hereditary Hemorrhagic Telangiectasia (HHT).
Funder: Health Resources and Services Administration
Due Dates: July 10, 2026 (Full application deadline)
Funding Amounts: Up to $2,900,000 total for one award; project period: 3 years (2026–2029)
Summary: Supports a national center to expand access, coordination, and data-driven care for Hereditary Hemorrhagic Telangiectasia (HHT).
Key Information: Only one application per organization; individuals are not eligible.
Description
This opportunity will fund a single national center to lead the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program. The program’s purpose is to reduce illness and mortality related to HHT by:
- Partnering with at least 15 clinical centers specializing in HHT to expand access and coordination of care.
- Leading quality improvement projects to enhance quality of life and access for people with HHT.
- Developing and maintaining a de-identified, aggregate patient data registry to better understand HHT and inform treatment.
- Piloting enhancements to electronic health record (EHR) systems to improve identification and diagnosis of HHT.
The funded center will serve as a national resource, supporting comprehensive multidisciplinary care, patient and provider education, and data-driven improvements in outcomes for this rare genetic disorder.
